Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-201
- Development stage
- Preclinical
- Lead developer
- BlissGene Therapeutics
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
BG-201 is a gene therapy candidate currently in the discovery phase, developed by BlissGene Therapeutics for the treatment of anxiety disorders. The therapeutic approach utilizes proprietary brain-selective lipid nanoparticles (LNPs) to deliver genetic material directly to the central nervous system. This genetic cargo is designed to modulate synaptic transmission, with the objective of promoting emotional equilibrium and reducing hyperarousal states in chronic anxiety models. The development of BG-201 is part of BlissGene's broader strategy to translate genetic insights from individuals with rare mutations conferring resilience to pain and emotional distress into precision medicines for neurological and psychiatric conditions.
Beyond the preview
Go deeper on BG-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-201.